Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q4 FY21 results · Jan–Mar 2021
Lincoln Pharmaceuticals reported revenue from operations of ₹77.54 crore (up 3.0% from Q4 FY20) and net profit of ₹11.85 crore (up 28.3% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a standalone basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 77.54 | 75.26 | +3.0% | 112.19 | −30.9% |
| Other income | 2.51 | 5.31 | −52.8% | 1.06 | +135.5% |
| Total income | 80.05 | 80.57 | −0.6% | 113.26 | −29.3% |
| Profit before tax | 14.79 | 11.38 | +29.9% | 18.16 | −18.5% |
| Net profit for the period | 11.85 | 9.23 | +28.3% | 13.37 | −11.4% |
| EPS, basic (₹) | 5.92 | 4.62 | +28.1% | 6.68 | −11.4% |
| Net margin (%) | 15.3 | 12.3 | 11.9 |
Standalone
- Filed with BSE
- 25 May 2021, 18:56 IST
- Board meeting
- 25 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE